Federal Register of Legislation - Australian Government

Primary content

PB 120 of 2010 Lists as made
This instrument amends the National Health Act 1953 - National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (No. PB 108 of 2010) to provide for additions, deletions and changes to forms, brands, responsible persons, circumstances for prescribing and to the maximum quantities and numbers of repeats that may be prescribed.
Administered by: Health
Registered 20 Dec 2010
Tabling HistoryDate
Tabled HR08-Feb-2011
Tabled Senate08-Feb-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 120 of 2010

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2010
(No. 1)1

National Health Act 1953

I, FELICITY McNEILL, Acting First Assistant Secretary, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 15 December 2010

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2010 (No. 1).

            (2)        This Instrument may also be cited as PB 120 of 2010.

2          Commencement

                        This Instrument commences on 1 January 2011.

3          Amendment of PB 108 of 2010

                        Schedule 1 amends PB 108 of 2010.



Schedule 1     Amendments

 

[1] Schedule 1, entry for Abacavir

omit from the column headed “Circumstances” (twice occurring):

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589

[2] Schedule 1, entry for Abacavir with Lamivudine

omit from the column headed “Circumstances”:

C1822  C1823  C3311  C3312

insert:

C3590  C3591  C3592  C3593

[3] Schedule 1, entry for Abacavir with Lamivudine and Zidovudine

omit from the column headed “Circumstances”:

C1822  C1823  C3311  C3312

insert:

C3590  C3591  C3592  C3593

[4] Schedule 1, entry for Aciclovir

substitute:

Aciclovir

Tablet 200 mg

Oral

Acihexal

SZ

MP NP

C3632 C3633

P3632

50

0

 

 

 

 

Acyclo-V 200

AF

MP NP

C3632 C3633

P3632

50

0

 

 

 

 

GenRx Aciclovir

GX

MP NP

C3632 C3633

P3632

50

0

 

 

 

 

Lovir

GM

MP NP

C3632 C3633

P3632

50

0

 

 

 

 

 

Zovirax 200 mg

GK

MP NP

C3632 C3633

P3632

50

0

 

 

 

 

Aciclovir 200

CR

MP NP

C3633

P3633

90

5

 

 

 

 

Acihexal

SZ

MP NP

C3632 C3633

P3633

90

5

 

 

 

 

Acyclo-V 200

AF

MP NP

C3632 C3633

P3633

90

5

 

 

 

 

Chem mart Aciclovir

CH

MP NP

C3633

P3633

90

5

 

 

 

 

GenRx Aciclovir

GX

MP NP

C3632 C3633

P3633

90

5

 

 

 

 

Lovir

GM

MP NP

C3632 C3633

P3633

90

5

 

 

 

 

Ozvir

RA

MP NP

C3633

P3633

90

5

 

 

 

 

Terry White Chemists Aciclovir

TW

MP NP

C3633

P3633

90

5

 

 

 

 

Zovirax 200 mg

GK

MP NP

C3632 C3633

P3633

90

5

 

 

Tablet 800 mg

Oral

Aciclovir 800

CR

MP NP

C3622 C3631

P3622 P3631

35

0

 

 

 

 

Acihexal

SZ

MP NP

C3622 C3630 C3631

P3622 P3631

35

0

 

 

 

 

Acyclo-V 800

AF

MP NP

C3622 C3630 C3631

P3622 P3631

35

0

 

 

 

 

GenRx Aciclovir

GX

MP NP

C3622 C3631

P3622 P3631

35

0

 

 

 

 

Zovirax 800 mg

GK

MP NP

C3622 C3631

P3622 P3631

35

0

 

 

 

 

Acihexal

SZ

MP NP

C3622 C3630 C3631

P3630

120

5

 

 

 

 

Acyclo-V 800

AF

MP NP

C3622 C3630 C3631

P3630

120

5

 

 

Eye ointment 30 mg per g, 4.5 g

Application to the eye

Zovirax

GK

MP NP AO

C1715

 

1

0

 

[5] Schedule 1, after entry for Amlodipine with valsartan in the form Tablet 5 mg (as besylate)-160 mg

insert:

 

Tablet 5 mg (as besylate)-320 mg

Oral

Exforge 5/320

NV

MP NP

C3307

 

28

5

 

 

[6] Schedule 1, after entry for Amlodipine with valsartan in the form Tablet 10 mg (as besylate)-160 mg

insert:

 

Tablet 10 mg (as besylate)-320 mg

Oral

Exforge 10/320

NV

MP NP

C3307

 

28

5

 

[7] Schedule 1, entry for Aprepitant

omit from the column headed “Circumstances”:

C2071  C2330  C3446

insert:

C3619  C3620  C3621

[8] Schedule 1, entry for Atazanavir

omit from the column headed “Circumstances” (all instances):

C1832  C1833  C3315  C3316

insert:

C3586  C3587  C3588  C3589

[9] Schedule 1, entry for Azathioprine in the form Tablet 25 mg

omit from the column headed “Brand”:         Azahexal            and insert:            Azathioprine Sandoz

[10]             Schedule 1, entry for Benzydamine

substitute:

Benzydamine

Mouth and throat rinse containing benzydamine hydrochloride 22.5 mg per 15 mL, 500 mL

Oral application

Difflam

IA

MP NP

C1669 C3634 C3635

P3635

1

0

 

 

 

 

 

 

PDP

C1669

 

1

0

 

 

 

 

 

 

MP NP

C1669 C3634 C3635

P1669

1

1

 

 

 

 

 

 

MP NP

C1669 C3634 C3635

P3634

1

3

 

 

[11]             Schedule 1, entry for Bisacodyl

substitute:

Bisacodyl

Tablet 5 mg

Oral

Bisalax

AS

MP NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643

P3643

200

0

 

 

 

 

Lax-Tab

AE

MP NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643

P3643

200

0

 

 

 

 

Bisalax

AS

MP NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643

P1025 P1122 P1221 P1254 P1263 P1268 P1400

200

2

 

 

 

 

Lax-Tab

AE

MP NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643

P1025 P1122 P1221 P1254 P1263 P1268 P1400

200

2

 

 

 

 

Bisalax

AS

MP NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643

P3642

200

3

 

 

 

 

Lax-Tab

AE

MP NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643

P3642

200

3

 

 

 

Tablets 5 mg, 200

Oral

Bisalax

AS

MP
See Note 1


See Note 3


See Note 3


See Note 3


See Note 3

PB

 

 

 

Lax-Tab

AE

MP
See Note 1


See Note 3


See Note 3


See Note 3


See Note 3

PB

 

Suppositories 10 mg, 10

Rectal

Dulcolax

BY

MP NP
See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

3
See Note 2

0
See Note 2

 

 

 

 

Petrus Bisacodyl Suppositories

PP

MP NP
See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

3
See Note 2

0
See Note 2

 

 

 

 

Dulcolax

BY

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

3
See Note 2

 

 

 

 

Petrus Bisacodyl Suppositories

PP

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

3
See Note 2

 

 

 

 

Dulcolax

BY

MP NP
See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

5
See Note 2

 

 

 

 

Petrus Bisacodyl Suppositories

PP

MP NP
See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

5
See Note 2

 

 

 

Suppositories 10 mg, 12

Rectal

Petrus Bisacodyl Suppositories

PP

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

3
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

3
See Note 2

 

 

 

 

 

 

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

4
See Note 2

 

 

Enemas 10 mg in 5 mL, 25

Rectal

Bisalax

AS

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

1
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP

See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

1
See Note 2

2
See Note 2

 

 

 

 

Petrus Bisacodyl Suppositories

PP

NP

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

5
See Note 2

 

 

[12]             Schedule 1, entry for Carvedilol in the form Tablet 3.125 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

APO-Carvedilol

TX

MP NP

C1735 C3234

 

30

0

 

[13]             Schedule 1, entry for Carmellose

omit:

 

Mouth spray containing carmellose sodium 10 mg per mL, 25 mL

Oral application

Aquae

HA

MP NP

C1899 C1900 C1901

P1901

1

0

 

 

 

 

 

 

MP NP

C1899 C1900 C1901

P1899 P1900

1

3

 

 

Mouth spray containing carmellose sodium 10 mg per mL, 100 mL

Oral application

Aquae

HA

MP NP

C1899 C1900 C1901

P1901

1

0

 

 

 

 

 

 

MP NP

C1899 C1900 C1901

P1899 P1900

1

3

 

insert in the columns in the order indicated:

 

Mouth spray containing carmellose sodium 10 mg per mL, 25 mL

Oral application

Aquae

HA

MP NP

C3636 C3637

P3637

1

0

 

 

 

 

 

 

MP NP

C3636 C3637

P3636

1

3

 

 

Mouth spray containing carmellose sodium 10 mg per mL, 100 mL

Oral application

Aquae

HA

MP NP

C3636 C3637

P3637

1

0

 

 

 

 

 

 

MP NP

C3636 C3637

P3636

1

3

 

 


[14]             Schedule 1, entry for Clonazepam

substitute:

Clonazepam

Tablet 500 micrograms

Oral

Paxam 0.5

AF

MP NP

C1574 C3657 C3658

P3658

100

0

 

 

 

 

Rivotril

RO

MP NP

C1574 C3657 C3658

P3658

100

0

 

 

 

 

Paxam 0.5

AF

MP NP

C1574 C3657 C3658

P3657

100

3

 

 

 

 

Rivotril

RO

MP NP

C1574 C3657 C3658

P3657

100

3

 

 

 

 

Paxam 0.5

AF

MP NP

C1574 C3657 C3658

P1574

200

2

 

 

 

 

Rivotril

RO

MP NP

C1574 C3657 C3658

P1574

200

2

 

 

Tablet 2 mg

Oral

Paxam 2

AF

MP NP

C1574 C3657 C3658

P3658

100

0

 

 

 

 

Rivotril

RO

MP NP

C1574 C3657 C3658

P3658

100

0

 

 

 

 

Paxam 2

AF

MP NP

C1574 C3657 C3658

P3657

100

3

 

 

 

 

Rivotril

RO

MP NP

C1574 C3657 C3658

P3657

100

3

 

 

 

 

Paxam 2

AF

MP NP

C1574 C3657 C3658

P3657

200

2

 

 

 

 

Rivotril

RO

MP NP

C1574 C3657 C3658

P1574

200

2

 

 

Oral liquid 2.5 mg per mL, 10 mL

Oral

Rivotril

RO

MP NP

C1574 C3657 C3658

P1574 P3658

2

0

 

 

 

 

 

RO

MP NP

C1574 C3657 C3658

P3657

2

3

 

 

Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)

Injection

Rivotril

RO

MP NP

C1093

 

5

0

 

 


[15]             Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Clopidogrel Actavis

GQ

MP NP

C1719 C1720 C1721 C1722 C1723 C1724

 

28

5

 

[16]             Schedule 1, entry for Darunavir

omit from the column headed “Circumstances” (twice occurring):

C3279  C3335

insert:

C3594 C3595

[17]             Schedule 1, entry for Diazepam

substitute:

Diazepam

Tablet 2 mg

Oral

Antenex 2

AF

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Valium

RO

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Valpam 2

SI

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Antenex 2

AF

MP NP

 

P3655

50

3

 

 

 

 

Valium

RO

MP NP

 

P3655

50

3

 

 

 

 

Valpam 2

SI

MP NP

 

P3655

50

3

 

 

 

 

 

 

 

 

 

 

 

 

 

Tablet 5 mg

Oral

Antenex 5

AF

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Diazepam-GA

GM

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Ranzepam

RA

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Valium

RO

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Valpam 5

SI

MP NP PDP

 

 

50

0

 

 

 

 

 

 

MP NP

 

P3656

50

0

 

 

 

 

Antenex 5

AF

MP NP

 

P3655

50

3

 

 

 

 

Diazepam-GA

GM

MP NP

 

P3655

50

3

 

 

 

 

Ranzepam

RA

MP NP

 

P3655

50

3

 

 

 

 

Valium

RO

MP NP

 

P3655

50

3

 

 

 

 

Valpam 5

SI

MP NP

 

P3655

50

3

 

 

Injection 10 mg in 2 mL

Injection

Hospira Pty Limited

HH

MP NP PDP

 

 

5

0

 

[18]             Schedule 1, entry for Diclofenac

substitute:

Diclofenac

Tablet (enteric coated) containing diclofenac sodium 25 mg

Oral

APO-Diclofenac

TX

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Chem mart Diclofenac

CH

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Clonac 25

SI

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Diclofenac-GA

GM

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Diclofenac Sandoz

SZ

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Fenac 25

AF

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Terry White Chemists Diclofenac

TW

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Voltaren 25

NV

MP NP

C1036 C1054

C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

APO-Diclofenac

TX

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Chem mart Diclofenac

CH

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Clonac 25

SI

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Diclofenac-GA

GM

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Diclofenac-GA

GM

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Fenac 25

AF

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Terry White Chemists Diclofenac

TW

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

 

 

Voltaren 25

NV

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

100

3

 

 

Tablet (enteric coated) containing diclofenac sodium 50 mg

Oral

APO-Diclofenac

TX

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Chem mart Diclofenac

CH

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Clonac 50

SI

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Diclofenac-GA

GM

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Diclofenac Sandoz

SZ

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Fenac

AF

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Terry White Chemists Diclofenac

TW

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

Voltaren 50

NV

MP NP

C1036 C1054

C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

P1036 P1054

50

0

 

 

 

 

APO-Diclofenac

TX

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Chem mart Diclofenac

CH

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Clonac 50

SI

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Diclofenac-GA

GM

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Diclofenac Sandoz

SZ

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Fenac

AF

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Terry White Chemists Diclofenac

TW

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

 

 

Voltaren 50

NV

MP NP

C1036 C1054

C3645 C3646

P1036 P1054

P3645

50

3

 

 

Suppository containing diclofenac sodium 100 mg

Rectal

Voltaren 100

NV

MP NP

 

P3666

40

0

 

 

 

 

 

 

PDP

 

 

40

0

 

 

 

 

 

 

MP NP MW

 

 

40

3

 

 

 

 

 

 

MP NP

 

P3665

40

3

 

[19]             Schedule 1, entry for Didanosine

omit from the column headed “Circumstances” (all instances):

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589

[20]             Schedule 1, after entry for Docetaxel in the form Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent

insert in the columns in the order indicated:

 

Solution concentrate for I.V. infusion 20 mg in 1 mL

Injection

Taxotere

SW

MP

See Note 1

C1194 C1742 C2416 C2439 C2732 C3051 C3292 C3428

P3051

1

0

 

 

 

 

 

 

MP

See Note 1

C1194 C1742 C2416 C2439 C2732 C3051 C3292 C3428

P1194 P1742 P2416 P2439 P2732 P3292 P3428

2

0

 

 

Solution concentrate for I.V. infusion 80 mg in 4 mL

Injection

Taxotere

SW

MP

See Note 1

C1194 C1742 C2416 C2439 C2732 C3051 C3292 C3428

 

1

0

 

[21]             Schedule 1, entry for Efavirenz

omit from the column headed “Circumstances” (all instances):

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589

[22]             Schedule 1, entry for Emtricitabine

omit from the column headed “Circumstances”:

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589

[23]             Schedule 1, entry for Enalapril in the form Tablet containing enalapril maleate 5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Enalapril-GA

GM

MP NP

 

 

30

5

 

[24]             Schedule 1, entry for Enfuvirtide

omit from the column headed “Circumstances”:

C2007  C2008  C3350  C3351

insert:

C3596  C3597

[25]             Schedule 1, entry for Etravirine

omit from the column headed “Circumstances”:

C2956  C3354

substitute:

C3596  C3597

[26]             Schedule 1, entry for Famciclovir

substitute:

Famciclovir

Tablet 125 mg

Oral

APO-Famciclovir

TX

MP NP

C3624

 

40

1

 

 

 

 

Ezovir

AF

MP NP

C3624

 

40

1

 

 

 

 

Famvir

NV

MP NP

C3624

 

40

1

 

 

 

 

Favic 125

SI

MP NP

C3624

 

40

1

 

 

Tablet 250 mg

Oral

APO-Famciclovir

TX

MP NP

C3622 C3623 C3624

P3624

20

1

 

 

 

 

Ezovir

AF

MP NP

C3622 C3623 C3624

P3624

20

1

 

 

 

 

Famciclovir Sandoz

SZ

MP NP

C3622 C3623 C3624

P3624

20

1

 

 

 

 

Famvir

NV

MP NP

C3622 C3623 C3624

P3624

20

1

 

 

 

 

Favic 250

SI

MP NP

C3622 C3623 C3624

P3624

20

1

 

 

 

 

APO-Famciclovir

TX

MP NP

C3622 C3623 C3624

P3622

21

0

 

 

 

 

Ezovir

AF

MP NP

C3622 C3623 C3624

P3622

21

0

 

 

 

 

Famciclovir Sandoz

SZ

MP NP

C3622 C3623 C3624

P3622

21

0

 

 

 

 

Famvir

NV

MP NP

C3622 C3623 C3624

P3622

21

0

 

 

 

 

Favic 250

SI

MP NP

C3622 C3623 C3624

P3622

21

0

 

 

 

 

APO-Famciclovir

TX

MP NP

C3622 C3623 C3624

P3623

56

5

 

 

 

 

Ezovir

AF

MP NP

C3622 C3623 C3624

P3623

56

5

 

 

 

 

Famciclovir Sandoz

SZ

MP NP

C3622 C3623 C3624

P3623

56

5

 

 

 

 

Famvir

NV

MP NP

C3622 C3623 C3624

P3623

56

5

 

 

 

 

Favic 250

SI

MP NP

C3622 C3623 C3624

P3623

56

5

 

 

Tablet 500 mg

Oral

Famvir

NV

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Favic 500

SI

MP NP

C3625 C3626 C3627 C3628 C3629

P3625

30

0

 

 

 

 

Ezovir

AF

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Famvir

NV

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

 

 

 

Favic 500

SI

MP NP

C3625 C3626 C3627 C3628 C3629

P3626 P3627 P3628 P3629

56

5

 

[27]             Schedule 1, omit entry for Fentanyl in the forms Lozenges 200 micrograms (as citrate), 3; Lozenges 400 micrograms (as citrate), 3; Lozenges 600 micrograms (as citrate), 3; Lozenges 800 micrograms (as citrate), 3; Lozenges 1200 micrograms (as citrate), 3; and Lozenges 1600 micrograms (as citrate), 3

insert in the columns in the order indicated:

Fentanyl

Lozenges 200 micrograms (as citrate), 3

Buccal

Actiq

OA

MP NP

C3663 C3664

P3663

3

0

 

 

 

 

 

 

MP NP

C3663 C3664

P3664

20

0

 

 

Lozenges 400 micrograms (as citrate), 3

Buccal

Actiq

OA

MP NP

C3663 C3664

P3663

3

0

 

 

 

 

 

 

MP NP

C3663 C3664

P3664

20

0

 

 

Lozenges 600 micrograms (as citrate), 3

Buccal

Actiq

OA

MP NP

C3663 C3664

P3663

3

0

 

 

 

 

 

 

MP NP

C3663 C3664

P3664

20

0

 

 

Lozenges 800 micrograms (as citrate), 3

Buccal

Actiq

OA

MP NP

C3663 C3664

P3663

3

0

 

 

 

 

 

 

MP NP

C3663 C3664

P3664

20

0

 

 

Lozenges 1200 micrograms (as citrate), 3

Buccal

Actiq

OA

MP NP

C3663 C3664

P3663

3

0

 

 

 

 

 

 

MP NP

C3663 C3664

P3664

20

0

 

 

Lozenges 1600 micrograms (as citrate), 3

Buccal

Actiq

OA

MP NP

C3663 C3664

P3663

3

0

 

 

 

 

 

 

MP NP

C3663 C3664

P3664

20

0

 

[28]             Schedule 1, entry for Fluconazole

omit from the column headed “Circumstances” (all instances):

C1199  C1854  C1855  C3240  C3295  C3296

insert:

C3613  C3614  C3615  C3616  C3617  C3618

[29]             Schedule 1, entry for Fosamprenavir in the form Tablet 700 mg (as calcium)

omit from the column headed “Responsible Person”: GK          and insert:            VI

[30]             Schedule 1, entry for Fosamprenavir

omit from the column headed “Circumstances” (twice occurring):

C1832  C1833  C3315  C3316

insert:

C3586  C3587  C3588  C3589


[31]             Schedule 1, entry for Frusemide in the form Injection 20 mg in 2 mL

omit from the column headed “Brand”:         Frusehexal        and insert:            Frusemide Sandoz

[32]             Schedule 1, entry for Gabapentin in the form Tablet 600 mg

omit:

 

 

 

Gabahexal 600mg

SZ

MP NP

C2664

 

100

5

 

[33]             Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride)

(a)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Gemcitabine Kabi

PK

MP
See Note 1

C1193 C1194 C1740 C2069 C2141

 

4

2

 

(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Gemcitabine Sun

ZF

MP
See Note 1

C1193 C1194 C1740 C2069 C2141

 

4

2

 

[34]             Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride)

(a)            insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Gemcitabine Kabi

PK

MP
See Note 1

C1193 C1194 C1740 C2069 C2141

 

2

2

 

(b)            insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Gemcitabine Sun

ZF

MP
See Note 1

C1193 C1194 C1740 C2069 C2141

 

2

2

 

 


[35]             Schedule 1, entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Gemcitabine Kabi

PK

MP
See Note 1

C1193 C1194 C1740 C2069 C2141

 

1

2

 

[36]             Schedule 1, entry for Gestrinone

omit from the column headed “Circumstances”:          C1377    and insert:            C3652

[37]             Schedule 1, entry for Glucose Indicator—Blood in the form Test strips, 50 (Bionime Rightest)

omit from the column headed “Responsible Person”: CQ          and insert:            QB

[38]             Schedule 1, entry for Glycerol

substitute:

Glycerol

Suppositories 700 mg, 12

Rectal

Petrus Pharmaceuticals Pty Ltd

PP

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

3
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

3
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

5
See Note 2

 

 

Suppositories 1.4 g, 12

Rectal

Petrus Pharmaceuticals Pty Ltd

PP

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

3
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

3
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C1025 C1122 C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

5
See Note 2

 

 

Suppositories 2.8 g, 12

Rectal

Petrus Pharmaceuticals Pty Ltd

PP

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3643
See Note 2

3
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P3642
See Note 2

3
See Note 2

3
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C1025 C1122
C1221 C1254 C1263 C1268 C1400 C3642 C3643
See Note 2

P1025 P1122 P1221 P1254 P1263 P1268 P1400
See Note 2

3
See Note 2

5
See Note 2

 

 


[39]             Schedule 1, entry for Granisetron

substitute:

Granisetron

Tablet 2 mg (as hydrochloride)

Oral

Kytril

HH

MP NP

See Note 1

C3050 C3611

See Note 2

P3050

See Note 2

2

See Note 2

0

See Note 2

 

 

 

 

 

 

MP NP

See Note 1

C3050 C3611

See Note 2

P3611

See Note 2

5

See Note 2

1

See Note 2

 

 

Concentrated injection 3 mg (as hydrochloride) in 3 mL

Injection

Granisetron Kabi

PK

MP NP

See Note 1

C3050 C3611

See Note 2

 

1

See Note 2

0

See Note 2

 

 

 

 

Kytril

HH

MP NP

See Note 1

C3050 C3611

See Note 2

 

1

See Note 2

0

See Note 2

 

[40]             Schedule 1, entry for Hyoscine

substitute:

Hyoscine

Injection containing hyoscine butylbromide 20 mg in 1 mL

Injection

Buscopan

BY

MP NP

C3638 C3639

P3639

30

0

 

 

 

 

 

 

MP NP

C3638 C3639

P3638

30

3

 

[41]             Schedule 1, entry for Hypromellose

omit:

 

Oral gel 20 mg per g, 100 g

Oral application

Aquae Gel

HA

MP NP

C1899 C1900 C1901

P1901

1

0

 

 

 

 

 

 

MP NP

C1899 C1900 C1901

P1899 P1900

1

3

 

insert in the columns in the order indicated:

 

Oral gel 20 mg per g, 100 g

Oral application

Aquae Gel

HA

MP NP

C3636 C3637

P3637

1

0

 

 

 

 

 

 

MP NP

C3636 C3637

P3636

1

3

 

 


[42]             Schedule 1, entry for Ibuprofen

substitute:

Ibuprofen

Tablet 400 mg

Oral

Brufen

AB

MP NP MW PDP

 

 

30

0

 

 

 

 

 

 

MP NP

 

P3666

90

0

 

 

 

 

 

 

PDP

 

P1036 P1054

90

0

 

 

 

 

 

 

MP NP

 

P1036 P1054 P3665

90

3

 

[43]             Schedule 1, entry for Indinavir

omit from the column headed “Circumstances”:

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589

[44]             Schedule 1, entry for Indomethacin

substitute:

Indomethacin

Capsule 25 mg

Oral

Arthrexin

AF

MP NP

C1036 C1054
C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Indocid

AS

MP NP

C1036 C1054
C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Arthrexin

AF

MP NP

C1036 C1054
C3645 C3646

P1036 P1054 P3645

100

3

 

 

 

 

Indocid

AS

MP NP

C1036 C1054
C3645 C3646

P1036 P1054 P3645

100

3

 

 

Suppository 100 mg

Rectal

Indocid

AS

MP NP

 

P3666

40

0

 

 

 

 

 

 

PDP

 

 

40

0

 

 

 

 

 

 

MP NP

 

 

40

3

 

 

 

 

 

 

MP NP

 

P3665

40

3

 

 


[45]             Schedule 1, entry for Itraconazole

omit all codes from the column headed “Circumstances” and substitute the following codes:

C3607  C3608  C3609  C3610  C3612  C3613  C3614

[46]             Schedule 1, omit entry for Ketoconazole in the form Tablet 200 mg

insert:

 

Tablet 200 mg

Oral

Nizoral

JC

MP NP

C3604 C3605 C3606

P3606

10

0

 

 

 

 

 

 

MP NP

C3604 C3605 C3606

P3604 P3605

30

5

 

[47]             Schedule 1, entry for Lactulose

substitute:

Lactulose

Solution BP 3.34 g per 5 mL, 500 mL

Oral

Actilax

AF

MP NP

C1150 C1613
C3642 C3643

P3643

3

0

 

 

 

 

Duphalac

SM

MP NP

C1150 C1613
C3642 C3643

P3643

3

0

 

 

 

 

Genlac

SI

MP NP

C1150 C1613
C3642 C3643

P3643

3

0

 

 

 

 

GenRx Lactulose

GX

MP NP

C1150 C1613
C3642 C3643

P3643

3

0

 

 

 

 

Lac-Dol

GM

MP NP

C1150 C1613
C3642 C3643

P3643

3

0

 

 

 

 

Lactocur

SZ

MP NP

C1150 C1613
C3642 C3643

P3643

3

0

 

 

 

 

Actilax

AF

MP NP

C1150 C1613
C3642 C3643

P3642

3

3

 

 

 

 

Duphalac

SM

MP NP

C1150 C1613
C3642 C3643

P3642

3

3

 

 

 

 

Genlac

SI

MP NP

C1150 C1613
C3642 C3643

P3642

3

3

 

 

 

 

GenRx Lactulose

GX

MP NP

C1150 C1613
C3642 C3643

P3642

3

3

 

 

 

 

Lac-Dol

GM

MP NP

C1150 C1613
C3642 C3643

P3642

3

3

 

 

 

 

Lactocur

SZ

MP NP

C1150 C1613
C3642 C3643

P3642

3

3

 

 

 

 

Actilax

AF

MP NP

C1150 C1613
C3642 C3643

P1150 P1613

1

5

 

 

 

 

Duphalac

SM

MP NP

C1150 C1613
C3642 C3643

P1150 P1613

1

5

 

 

 

 

Genlac

SI

MP NP

C1150 C1613
C3642 C3643

P1150 P1613

1

5

 

 

 

 

GenRx Lactulose

GX

MP NP

C1150 C1613
C3642 C3643

P1150 P1613

1

5

 

 

 

 

Lac-Dol

GM

MP NP

C1150 C1613
C3642 C3643

P1150 P1613

1

5

 

 

 

 

Lactocur

SZ

MP NP

C1150 C1613
C3642 C3643

P1150 P1613

1

5

 

[48]             Schedule 1, entry for Lamivudine in each of the forms Tablet 150 mg; Tablet 300 mg; and Oral solution 10 mg per mL, 240 mL

omit from the column headed “Circumstances”:

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589

[49]             Schedule 1, entry for Lamivudine with Zidovudine

omit from the column headed “Circumstances”:

C1820  C1821  C3309  C3310

insert:

C3586  C3587  C3588  C3589


[50]             Schedule 1, entry for Lercanidipine in the forms Tablet containing lercanidipine hydrochloride 10 mg and Tablet containing lercanidipine hydrochloride 20 mg

(a)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Lercan

SI

MP NP

 

 

28

5

 

(b)           insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

 

 

 

Lercanidipine Sandoz

SZ

MP NP

 

 

28

5

 

[51]             Schedule 1, entry for Lopinavir with Ritonavir

omit from the column headed “Circumstances” (all instances):

C1832  C1833  C3315  C3316

insert:

C3586  C3587  C3588  C3589

[52]             Schedule 1, entry for Macrogol 3350

substitute:

Macrogol 3350

Sachets containing powder for oral solution 13.125 g with electrolytes, 30

Oral

Movicol

NE

MP NP

See Note 1

C1263 C1613
C2693 C2823 C3642 C3643

See Note 2

P3643
See Note 2

2
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP

See Note 1

C1263 C1613
C2693 C2823 C3642 C3643

See Note 2

P3642
See Note 2

2
See Note 2

3
See Note 2

 

 

 

 

 

 

MP NP

See Note 1

C1263 C1613
C2693 C2823 C3642 C3643

See Note 2

P1263 P1613
P2693 P2823
See Note 2

1
See Note 2

5
See Note 2

 

 

Powder for oral solution 510 g

Oral

MediHealth ClearLax

ON

MP NP

C1263 C1613
C2693 C2823 C3642 C3643

P3643

2

0

 

 

 

 

OsmoLax

KY

MP NP

C1263 C1613
C2693 C2823 C3642 C3643

P3643

2

0

 

 

 

 

MediHealth ClearLax

ON

MP NP

C1263 C1613
C2693 C2823 C3642 C3643

P3642

2

3

 

 

 

 

OsmoLax

KY

MP NP

C1263 C1613
C2693 C2823 C3642 C3643

P3642

2

3

 

 

 

 

MediHealth ClearLax

ON

MP NP

C1263 C1613
C2693 C2823 C3642 C3643

P1263 P1613 P2693 P2823

1

5

 

 

 

 

OsmoLax

KY

MP NP

C1263 C1613
C2693 C2823 C3642 C3643

P1263 P1613 P2693 P2823

1

5

 

[53]             Schedule 1, entry for Maraviroc

(a)           omit from the column headed “Responsible Person” (twice occurring):                VI            and insert:            PF

(b)           omit from the column headed “Circumstances” (twice occurring):

C3286  C3406

insert:

C3598  C3599

[54]             Schedule 1, after entry for Mesalazine in the form Suppository 1 g

insert in the columns in the order indicated:

 

Suppository 1g (moulded)

Rectal

Salofalk

OA

MP NP

C1978

 

30

1

 

[55]             Schedule 1, entry for Metformin in the form Tablet (extended release) containing metformin hydrochloride 1 g

omit from the column headed “Responsible Person”: AF          and insert:            AL

[56]             Schedule 1, entry for Methadone

omit:

 

Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL

Oral

Biodone Forte

MW

MP NP
See Note 1

See Note 2

See Note 2

See Note 2

See Note 2

PB

 

 

 

Sigma Pharmaceuticals (Australia) Pty Ltd

SI

MP NP

See note 1

C2348 C2349 C2350
See Note 2

P2350
See Note 2

1
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP

C2348 C2349 C2350
See Note 2

P2348 P2349
See Note 2

1
See Note 2

2
See Note 2

 

insert in the columns in the order indicated:

 

Oral liquid containing methadone hydrochloride 25 mg per 5 mL, 200 mL

Oral

Biodone Forte

MW

MP NP
See Note 1

See Note 3

See Note 3

See Note 3

See Note 3

PB

 

 

 

Sigma Pharmaceuticals (Australia) Pty Ltd

SI

MP NP
See Note 1

C3659 C3660
See Note 2

P3660
See Note 2

1
See Note 2

0
See Note 2

 

 

 

 

 

 

MP NP
See Note 1

C3659 C3660
See Note 2

P3659
See Note 2

1
See Note 2

2
See Note 2

 

[57]             Schedule 1, entry for Methylnaltrexone

substitute:

Methylnaltrexone

Solution for injection containing methylnaltrexone bromide 12 mg in 0.6 mL

Injection

Relistor

WX

MP NP

C3235 C3238

P3235

3

0

 

 

 

 

 

 

MP NP

C3235 C3238

P3238

7

0

 

[58]             Schedule 1, entry for Morphine

(a)     omit:

 

Tablet containing morphine sulfate 10 mg

Oral

Sevredol

MF

MP NP

C1789 C2351 C2352 C2353

P1789 P2353

20

0

 

 

 

 

 

 

MP NP

C1789 C2351 C2352 C2353

P2351 P2352

20

2

 

 

Tablet containing morphine sulfate 20 mg

Oral

Sevredol

MF

MP NP

C1789 C2351 C2352 C2353

P1789 P2353

20

0

 

 

 

 

 

 

MP NP

C1789 C2351 C2352 C2353

P2351 P2352

20

2

 

insert in the columns in the order indicated:

 

Tablet containing morphine sulfate 10 mg

Oral

Sevredol

MF

MP NP

C1789 C3661 C3662

P1789 P3662

20

0

 

 

 

 

 

 

MP NP

C1789 C3661 C3662

P1789 P3661

20

2

 

 

Tablet containing morphine sulfate 20 mg

Oral

Sevredol

MF

MP NP

C1789 C3661 C3662

P1789 P3662

20

0

 

 

 

 

 

 

MP NP

C1789 C3661 C3662

P1789 P3661

20

2

 

(b)     omit:

 

Tablet containing morphine sulfate 200 mg (controlled release)

Oral

MS Contin

MF

MP NP

C1499 C2348 C2349 C2350

P1499 P2350

20

0

 

 

 

 

 

 

MP NP

C1499 C2348 C2349 C2350

P2348 P2349

20

2

 

insert in the columns in the order indicated:

 

Tablet containing morphine sulfate 200 mg (controlled release)

Oral

MS Contin

MF

MP NP

C1499 C3659 C3600

P1499 P3660

20

0

 

 

 

 

 

 

MP NP

C1499 C3659 C3600

P3659

20

2

 

[59]             Schedule 1, entry for Naproxen

substitute:

Naproxen

Tablet 250 mg

Oral

Inza 250

AF

MP NP

C1036 C1054
C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Naprosyn

RO

MP NP

C1036 C1054
C3645 C3646

P3646

100

0

 

 

 

 

 

 

PDP

C1036 C1054

 

100

0

 

 

 

 

Inza 250

AF

MP NP

C1036 C1054
C3645 C3646

P1036 P1054
P3645

100

3

 

 

 

 

Naprosyn

RO

MP NP

C1036 C1054
C3645 C3646

P1036 P1054
P3645

100

3

 

 

Tablet containing naproxen sodium 550 mg

Oral

Anaprox 550

RO

MP NP

C1036 C1054
C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

 

50

0

 

 

 

 

Crysanal

MD

MP NP

C1036 C1054
C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP

C1036 C1054

 

50

0

 

 

 

 

Anaprox 550

RO

MP NP

C1036 C1054
C3645 C3646

P1036 P1054
P3645

50

3

 

 

 

 

Crysanal

MD

MP NP

C1036 C1054
C3645 C3646

P1036 P1054
P3645

50

3

 

 

Tablet 500 mg

Oral

Inza 500

AF

MP NP

C1036 C1054
C3645 C3646

P3646

50

0

 

 

 

 

 

 

PDP